Watch More! Unlock the full videos with a FREE trial
Add to Study plan
Master
Included In This Lesson
Access More! View the full outline and transcript with a FREE trial
Outline
What is the generic name?
AXITINIB
What is the Trade Name for AXITINIB?
INLYTA
What are the Indications for AXITINIB?
- 1 INDICATIONS AND USAGE INLYTA is a kinase inhibitor indicated: in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). ( 1.1 ) in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC. ( 1.1 ) as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. ( 1.2 ) 1.1 First-Line Advanced Renal Cell Carcinoma INLYTA in combination with avelumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC). INLYTA in combination with pembrolizumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma. 1.2 Second-Line Advanced Renal Cell Carcinoma INLYTA as a single agent is indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
View Our Nursing Pharmacology Course
References: https://open.fda.gov/
Other Pharm Resources
View the FULL Outline
When you start a FREE trial you gain access to the full outline as well as:
- SIMCLEX (NCLEX Simulator)
- 6,500+ Practice NCLEX Questions
- 2,000+ HD Videos
- 300+ Nursing Cheatsheets
“Would suggest to all nursing students . . . Guaranteed to ease the stress!”
~Jordan